NasdaqGS:PHVSPharmaceuticals
Assessing Pharvaris (PHVS) Valuation After 2025 Earnings Loss And Deucrictibant Milestone Updates
Why Pharvaris’ Latest Earnings Matter for Investors
Pharvaris (PHVS) reported a full year 2025 net loss of €175.7 million, along with updates on key hereditary angioedema programs that included completed CHAPTER-3 Phase 3 enrollment and a reaffirmed FDA filing timeline for deucrictibant.
See our latest analysis for Pharvaris.
Despite the wider net loss and heavier R&D commitment, Pharvaris’ share price has climbed, with a 30 day share price return of 9.49% and a 90 day gain of 17.96%. The 1...